SCHEMBL2658291

SCHEMBL2658291

COc1ccc(-c2c(F)ccc3c(N)c4c(nc23)CN(C2=CC=C2)C4=O)cc1OC

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 4/20 0.35
▸ CA2 P00918 4/20 0.35
▸ BCL9 O00512 1/20 0.35
▸ CTNNB1 P35222 1/20 0.35
▸ PTGS2 P35354 2/20 0.34
▸ GABRG2 P18507 4/20 0.33
▸ GABRB3 P28472 4/20 0.33
▸ GABRA2 P47869 4/20 0.33
▸ USP2 O75604 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ HPGD P15428 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ PIK3CA P42336 1/20 0.32
▸ ABCG2 Q9UNQ0 2/20 0.32
▸ KCNQ3 O43525 1/20 0.31
▸ KCNQ2 O43526 1/20 0.31
▸ PDPK1 O15530 1/20 0.31
▸ ABCB1 P08183 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2658971 0.86 GABRG2 (0.39) GABRG2GABRB3GABRA2
SCHEMBL2659113 0.86 GABRG2 (0.47) GABRG2GABRB3GABRA2
SCHEMBL2657148 0.85 MTOR (0.35) GABRG2GABRB3GABRA2PIK3CA
SCHEMBL2660626 0.85 GABRG2 (0.37) GABRG2GABRB3GABRA2
SCHEMBL2657622 0.84 UGCG (0.35) GABRG2GABRB3GABRA2KDM4EALDH1A1
SCHEMBL2657000 0.84 GABRG2 (0.46) GABRG2GABRB3GABRA2KDM4E
SCHEMBL2656086 0.83 PDE5A (0.41) CA1CA2BCL9CTNNB1PTGS2
SCHEMBL4916255 0.83 GABRG2 (0.33) GABRG2GABRB3GABRA2
SCHEMBL2655965 0.83 GABRG2 (0.40) GABRG2GABRB3GABRA2
SCHEMBL2660960 0.83 PDE4A (0.41) CA1CA2BCL9CTNNB1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF CA1 568/4885CA2 4588/4885BCL9 3874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback